Study finds emodepside formulations in dogs are not bioequivalent

A newly published study is giving veterinarians clearer evidence that emodepside formulations can't be assumed to behave the same way in dogs. In the American Journal of Veterinary Research, investigators reported that the FDA-approved feline topical solution and the European Medicines Agency-approved canine oral modified-release tablet were not bioequivalent when used in dogs, despite containing the same active ingredient. That finding lands at a time when emodepside is drawing attention as one of the few remaining options for difficult cases of multidrug-resistant canine hookworm infection. (pubmed.ncbi.nlm.nih.gov)

The background is the growing challenge of multianthelmintic drug-resistant Ancylostoma caninum in dogs. Earlier field and kennel reports have shown poor performance from standard products in some populations, while emodepside has produced much stronger fecal egg count reductions in resistant infections. Emodepside is also notable pharmacologically: as discussed in the AVMA’s Veterinary Vertex podcast on the paper, it belongs to the octadepsipeptide class and has a mechanism of action distinct from other marketed anthelmintics, helping explain why it has become a focus in resistant hookworm cases. Because emodepside isn't approved for dogs in the United States, some clinicians have turned to extra-label oral administration of the feline topical product, Profender, under AMDUCA, especially after failure of triple-drug protocols confirmed by fecal egg count reduction testing. (vtechworks.lib.vt.edu)

That workaround is what the new study set out to test more rigorously. According to the publication and an earlier Kansas State research abstract, seven client-owned dogs were enrolled in a crossover pharmacokinetic study comparing the feline topical formulation and the canine oral formulation. The published results found that topical administration of the feline product produced plasma emodepside concentrations 36- to 122-fold lower than oral administration. Just as importantly, when the feline topical formulation was administered orally at 1 mg/kg, it still failed bioequivalence testing against the canine oral tablet given at the same dose. In fact, the oral feline topical product produced substantially greater systemic exposure, with an approximately threefold higher Cmax and 2.4- to 2.8-fold greater AUC than the canine modified-release tablet. In other words, matching the active ingredient didn't produce matching exposure—and the difference went in both directions depending on route. (pubmed.ncbi.nlm.nih.gov)

That conclusion lines up with prior expert commentary. In Clinician’s Brief, Ray Kaplan and Pablo David Jimenez Castro wrote that drug formulation matters because excipients are chosen to optimize pharmacokinetics and safety for a specific route, and topical excipients aren't intended for oral use. The same article notes that the suggested extra-label oral dose in dogs is 1 mg/kg, about one-third of the feline topical labeled dose, and stresses that precise calculation is essential. AAHA coverage of related guidance has also highlighted additional concerns, including the risk of rapid heartworm kill in infected dogs and the potential for severe adverse effects in dogs with the MDR1 mutation if dosing is inaccurate. The AVMA podcast discussion reinforced the same practical point, emphasizing the FDA definition of bioequivalence as equivalence in both the rate and extent of absorption—and showing that this standard was not met here. (cliniciansbrief.com)

The industry and academic reaction so far has been less about splashy debate and more about clinical caution. Kansas State investigators had previewed the question in a 2024 research abstract, framing the issue as whether the feline topical product administered orally could achieve the same blood concentrations as the effective canine oral formulation. A later Utah State University magazine feature summarized the practical takeaway even more plainly, noting that formulation differences can change exposure and safety, and that bioequivalence can't be assumed. That measured tone fits the broader parasitology conversation: emodepside remains promising, but only with careful case selection and monitoring. (vet.k-state.edu)

Why it matters: For veterinary professionals, the biggest implication is that extra-label emodepside use in dogs now has stronger evidence against treating formulations as interchangeable. In practice, that affects informed consent, dose calculation, route selection, monitoring, and expectations for treatment response. It also reinforces a stepwise approach: confirm treatment failure with FECRT, consider resistance testing where available, screen for heartworm infection, think about MDR1 status in at-risk breeds, and administer in-clinic when emodepside is used. For practices seeing persistent hookworm cases, this paper supports a more conservative, pharmacology-driven conversation with pet parents and may reduce overconfidence in oral use of a feline topical product. It also sharpens a subtler point: oral use of the feline topical product is not simply a weaker stand-in for the canine tablet. Based on this study, it can produce higher peak and overall exposure than the canine modified-release formulation, which has implications for both efficacy assumptions and safety discussions. (cliniciansbrief.com)

What to watch: The next questions are whether these pharmacokinetic differences translate into meaningful differences in clinical efficacy across resistant cases, whether more formal U.S. guidance emerges around extra-label emodepside protocols, and whether demand grows for a canine oral formulation in the U.S. market. For now, the timeline is clear: the AJVR paper was published online April 4, 2025, and it gives clinicians a stronger evidence base heading into the next round of hookworm management decisions.